Cargando…
Remimazolam as an Adjunct to General Anesthesia in Children: Adverse Events and Outcomes in a Large Cohort of 418 Cases
Remimazolam was first approved in 2020 as a general anesthetic for adults and still does not have pediatric labeling. Our study will be the first pilot program that administers remimazolam as an adjunct to a general endotracheal anesthetic in children. Between August 2020 and December 2022, electron...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299672/ https://www.ncbi.nlm.nih.gov/pubmed/37373624 http://dx.doi.org/10.3390/jcm12123930 |
_version_ | 1785064421895176192 |
---|---|
author | Kimoto, Yoshitaka Hirano, Tatsuya Kuratani, Norifumi Cavanaugh, David Mason, Keira P. |
author_facet | Kimoto, Yoshitaka Hirano, Tatsuya Kuratani, Norifumi Cavanaugh, David Mason, Keira P. |
author_sort | Kimoto, Yoshitaka |
collection | PubMed |
description | Remimazolam was first approved in 2020 as a general anesthetic for adults and still does not have pediatric labeling. Our study will be the first pilot program that administers remimazolam as an adjunct to a general endotracheal anesthetic in children. Between August 2020 and December 2022, electronic medical records were collected for all children who received remimazolam during anesthesia. The remimazolam dosing regimen was extrapolated from the adult package insert, with intravenous induction doses of 12 mg/kg/h administered until the desired effect was achieved. Subsequent infusions were given at a rate of 1–2 mg/kg/h, accompanied by intermittent boluses of 0.2 mg/kg, with all dosing adjustments made according to the anesthesiologist’s clinical discretion. A total of 418 children (mean 4.6 yrs, 68.7% ASA 1 and 2) underwent surgeries which averaged 81.2 min. A total of 75.2% of patients had greater than a 20% change (increase or decrease) in MAP (lowest or highest) from baseline, and 203 (49.3%) patients had greater than a 30% change (increase or decrease) in MAP (lowest or highest) from baseline. A total of 5% received ephedrine to treat unanticipated hemodynamic variability. Discharge criteria were met within an average of 13.8 min after arrival at the post-anesthesia care unit. Remimazolam may offer the benefits of rapid recovery following general endotracheal anesthesia. The risk of hemodynamic variability which necessitates and responds to ephedrine should be anticipated. |
format | Online Article Text |
id | pubmed-10299672 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102996722023-06-28 Remimazolam as an Adjunct to General Anesthesia in Children: Adverse Events and Outcomes in a Large Cohort of 418 Cases Kimoto, Yoshitaka Hirano, Tatsuya Kuratani, Norifumi Cavanaugh, David Mason, Keira P. J Clin Med Article Remimazolam was first approved in 2020 as a general anesthetic for adults and still does not have pediatric labeling. Our study will be the first pilot program that administers remimazolam as an adjunct to a general endotracheal anesthetic in children. Between August 2020 and December 2022, electronic medical records were collected for all children who received remimazolam during anesthesia. The remimazolam dosing regimen was extrapolated from the adult package insert, with intravenous induction doses of 12 mg/kg/h administered until the desired effect was achieved. Subsequent infusions were given at a rate of 1–2 mg/kg/h, accompanied by intermittent boluses of 0.2 mg/kg, with all dosing adjustments made according to the anesthesiologist’s clinical discretion. A total of 418 children (mean 4.6 yrs, 68.7% ASA 1 and 2) underwent surgeries which averaged 81.2 min. A total of 75.2% of patients had greater than a 20% change (increase or decrease) in MAP (lowest or highest) from baseline, and 203 (49.3%) patients had greater than a 30% change (increase or decrease) in MAP (lowest or highest) from baseline. A total of 5% received ephedrine to treat unanticipated hemodynamic variability. Discharge criteria were met within an average of 13.8 min after arrival at the post-anesthesia care unit. Remimazolam may offer the benefits of rapid recovery following general endotracheal anesthesia. The risk of hemodynamic variability which necessitates and responds to ephedrine should be anticipated. MDPI 2023-06-08 /pmc/articles/PMC10299672/ /pubmed/37373624 http://dx.doi.org/10.3390/jcm12123930 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kimoto, Yoshitaka Hirano, Tatsuya Kuratani, Norifumi Cavanaugh, David Mason, Keira P. Remimazolam as an Adjunct to General Anesthesia in Children: Adverse Events and Outcomes in a Large Cohort of 418 Cases |
title | Remimazolam as an Adjunct to General Anesthesia in Children: Adverse Events and Outcomes in a Large Cohort of 418 Cases |
title_full | Remimazolam as an Adjunct to General Anesthesia in Children: Adverse Events and Outcomes in a Large Cohort of 418 Cases |
title_fullStr | Remimazolam as an Adjunct to General Anesthesia in Children: Adverse Events and Outcomes in a Large Cohort of 418 Cases |
title_full_unstemmed | Remimazolam as an Adjunct to General Anesthesia in Children: Adverse Events and Outcomes in a Large Cohort of 418 Cases |
title_short | Remimazolam as an Adjunct to General Anesthesia in Children: Adverse Events and Outcomes in a Large Cohort of 418 Cases |
title_sort | remimazolam as an adjunct to general anesthesia in children: adverse events and outcomes in a large cohort of 418 cases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299672/ https://www.ncbi.nlm.nih.gov/pubmed/37373624 http://dx.doi.org/10.3390/jcm12123930 |
work_keys_str_mv | AT kimotoyoshitaka remimazolamasanadjuncttogeneralanesthesiainchildrenadverseeventsandoutcomesinalargecohortof418cases AT hiranotatsuya remimazolamasanadjuncttogeneralanesthesiainchildrenadverseeventsandoutcomesinalargecohortof418cases AT kurataninorifumi remimazolamasanadjuncttogeneralanesthesiainchildrenadverseeventsandoutcomesinalargecohortof418cases AT cavanaughdavid remimazolamasanadjuncttogeneralanesthesiainchildrenadverseeventsandoutcomesinalargecohortof418cases AT masonkeirap remimazolamasanadjuncttogeneralanesthesiainchildrenadverseeventsandoutcomesinalargecohortof418cases |